Coloplast A/S Reports Strong Q3 Results for 2024/25
Coloplast A/S recently shared its interim financial results for the third quarter of the 2024/25 fiscal year, demonstrating impressive organic growth and stable profit margins. The company achieved a remarkable 7% organic growth and reported an EBIT margin of 28% in Q3, reflecting its commitment to enhancing patient care and advancing its products.
Financial Highlights
The reported revenue in Danish Krone (DKK) grew by 1%, despite facing currency challenges and the impact from the recent divestment of its Skin Care segment. Below are some key figures from the quarter:
- Ostomy Care grew by 6%, Continence Care by 8%, Voice and Respiratory Care by 9%, Advanced Wound Care increased by 4%, and Interventional Urology also saw a growth of 4%.
- Continued success in the Luja™ portfolio contributed significantly to the growth of Continuum Care.
- Although Advanced Wound Dressing reported a -2% growth, driven mainly by the product return in China, the company anticipates a recovery in growth momentum moving forward.
Challenges and Opportunities
In the latest quarter, Kerecis, a key partner, achieved impressive growth of 17% with an EBIT margin of 13%. However, the quarter was marked by a temporary slowdown in the out-patient setting, reducing utilization of certain products. The company expects growth momentum to improve in the next quarter as market conditions stabilize.
Additionally, growth in the Interventional Urology segment was positively influenced by trends in the U.S. Men's Health market, albeit slightly tempered by a product recall affecting Bladder Health.
Overall Performance for 9M 2024/25
For the first nine months of the fiscal year, Coloplast delivered an organic growth of 7% and maintained an EBIT margin of 27%, with reported revenue growing 4% to DKK 20,914 million. Some notable metrics include:
- The organic growth rates across various business segments providing a well-rounded performance.
- An EBIT of DKK 5,718 million, illustrating a 4% rise year over year.
- Adjusted net profit before special items declines were minor, impacted primarily by non-cash financial expenses.
Looking Ahead: Guidance for FY 2024/25
The guidance for the current fiscal year remains steady, with expectations of organic growth around 7% and EBIT margin before special items projected at 27-28%. The company notes adjustments in projected revenue growth due to various factors, especially the impact of currency fluctuations and divestments.
Coloplast’s interim CEO Lars Rasmussen expressed satisfaction with the organization’s performance and emphasized the company’s commitment to delivering on its priorities as they prepare for the 2030 strategy presentation at the upcoming Capital Markets Day.
Investing In the Future
Coloplast A/S is rooted in innovation and is dedicated to improving the quality of life for individuals with intimate healthcare needs. Their long-standing mission aligns with their business strategy, fostering development in product segments such as Ostomy Care, Continence Care, Advanced Wound Care, and more.
Frequently Asked Questions
What were the organic growth rates for the different business areas?
The organic growth rates are: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4%, and Interventional Urology 4%.
How did Coloplast perform in terms of EBIT margin?
Coloplast achieved an EBIT margin of 28% in Q3 and 27% for the 9 months ending in 2024/25.
What challenges did Coloplast face in the reporting period?
The main challenges included product returns in the Advanced Wound Dressings segment and impacts from currency fluctuations.
What is the guidance for the remainder of the fiscal year?
The company is maintaining guidance for organic growth of around 7% and an EBIT margin of 27-28%.
Who can investors contact for more information?
Investors can reach out to Anders Lonning-Skovgaard, Executive Vice President and CFO, or Aleksandra Dimovska, Vice President of Investor Relations, for further information.
